IDPS HomeInfectious Diseases A-CD-GH-LM-QR-ST-ZDisease ReportingHealthcare SafetyIDPS Health TopicsImmunization UnitRelated DSHS SitesRelated Rules & RegulationsVaccine Preventable DiseasesAbout IDPS
  • Contact Us

    Infectious Disease Prevention Section
    Mail Code: 1927
    PO BOX 149347 - Austin, TX 78714-9347
    1100 West 49th Street, Suite G401
    Austin, TX 78714

    Phone: (512) 776-7676
    Fax: (512) 776-7616


    E-mail

Screening Recommendations


The following individuals should be screened for Candida auris:

  • Anyone who, over the four weeks prior to specimen collection, shared a room with an individual identified with C. auris infection or colonization, regardless of the use of contact precautions or length of stay.

  • All patients in the same healthcare area that overlap in healthcare stay with an individual identified with C. auris infection or colonization, regardless of the use of contact precautions.

  • Patients currently occupying a room that previously housed an individual identified with C. auris.

  • Individuals with current multidrug-resistant gram negative bacteria that received healthcare outside of the US within the last 12 months.

  • Patients transferring from a unit or facility with current transmission of C. auris or recent transmission within the last 30 days.

Notes:

  • Facilities should consider adding C. auris to existing multidrug-resistant organism (MDRO) screening protocols, via a composite swab of the patient’s bilateral axilla and groin. For guidance on performing swab testing in-house, refer to: https://www.cdc.gov/fungal/candida-auris/c-auris-guidance.html.

  • All ages are at risk for C. auris infections.

  • Routine screening of healthcare workers and the environment are not recommended unless epidemiological evidence links to transmission or where transmission persists despite other interventions.
Last updated July 2, 2021